Cognito Therapeutics Announces Presentation of New CSF Proteomic and EEG Biomarker Data for Spectris™ in Alzheimer’s Disease at CTAD 2025 Cognito Therapeutics, a clinical-stage medical device company ...
Alzheimer's pathology was common in other dementias. An Alzheimer's biomarker profile was seen in unspecified dementia, Parkinson's dementia, and frontotemporal dementia. Biomarkers indicating ...
Brain-derived extracellular vesicle (EV) biomarkers represent a promising frontier for liquid biopsy development targeting the nervous system. They offer strong potential for enabling minimally ...
A fully automated plasma biomarker panel detected amyloid-beta (Aβ) positivity and monitored early amyloid accumulation in middle-aged cognitively unimpaired (CU) adults at risk for Alzheimer's ...
Global prevalence estimates show Alzheimer’s disease accounts for most dementia, with ~57 million people affected in 2021 and numbers projected to triple by 2050. People and health systems face rising ...
OTTAWA, Ontario — Looking for Alzheimer’s disease (AD) biomarkers in plasma instead of cerebrospinal fluid (CSF) is a simpler form of screening individuals for AD pathology and could result in earlier ...
GENT, Belgium & MALVERN, PA & TOKYO, Japan — A new laboratory test aimed at detecting Alzheimer’s disease earlier in its progression is now available to researchers, marking a potential advance in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results